National Institute for Bioprocessing Research and Training, Ireland, and GE Healthcare Life Sciences announce biopharmaceutical research collaboration
Joint research project to drive new technologies for the development and functional analysis of therapeutic antibodies
Dublin, Ireland and Chalfont St Giles, UK - The National Institute for Bioprocessing Research and Training (NIBRT), Ireland and GE Healthcare Life Sciences today announced a joint research collaboration to drive advances in technologies for the development and functional analysis of therapeutic antibodies, protein-based drugs that are increasingly used to treat diseases such as cancer, rheumatoid arthritis and multiple sclerosis. The NIBRT and GE Healthcare are investing $0.5 million the first year in this project, which is planned to run for two years.
The goal of the collaboration is to develop new, robust and reproducible biochemical assays for the analysis of the biological activity of therapeutic monoclonal antibodies. Current industry-standard techniques for research and manufacture often rely on cell-based assays, which can be non-quantitative, labour intensive and highly variable. The collaboration will combine NIBRT’s leading expertise in in glycobiology and novel bioanalytical techniques with GE Healthcare’s capabilities in protein-protein interaction analysis, particularly the company’s Biacore™ SPR technology.
Welcoming the collaboration, Professor Ian Marison, NIBRT Interim Director said: “We are delighted with this research collaboration with GE Healthcare, which will allow NIBRT to apply its bioanalytical expertise to develop novel analytical platforms for the determination of monoclonal antibody biological activity. We look forward to working with GE Healthcare on this exciting project and developing our relationship further over time”.
The research will be led by NIBRT’s Principal Investigator and global leader in glycobiology, Professor Pauline Rudd, in conjunction with researchers from GE Healthcare Life Sciences laboratories in Uppsala, Sweden.
Dr. Lotta Ljungqvist, Head of Research and Development for the BioTechnologies business of GE Healthcare Life Sciences said, “Our goal is to help our customers optimize every step of their discovery, development and biopharmaceutical manufacturing process, and so help reduce cost of entry, deliver higher yields of finished product and reduce time to market. This collaboration will help us to drive the development of new, biologically relevant and fully characterized binding assays for measuring antibody activity, a critical step in the design and manufacture of effective monoclonal antibody based therapies. We look forward to a productive collaboration with the talented team at NIBRT.”
The National Institute for Bioprocessing Research and Training (NIBRT) is a global centre of excellence for training and research in bioprocessing. NIBRT is located in a new, world class facility in Dublin, Ireland. This facility is purpose built to closely replicate a modern bioprocessing plant with state of the art equipment.
NIBRT is based on an innovative collaboration between University College Dublin, Trinity College Dublin, Dublin City University and the Institute of Technology, Sligo. NIBRT was primarily funded by the Government of Ireland through Ireland’s inward investment promotion agency, IDA Ireland (Industrial Development Agency), which is responsible for the attraction and development of foreign investment in Ireland. NIBRT offers a quality training and research experience not previously possible anywhere in the world.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.
Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
For more information about GE Healthcare Life Sciences’ technologies and services, please visit www.gelifesciences.com
For our latest news, please visit http://newsroom.gehealthcare.com
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.